Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Yuhan Out-Licenses NASH Treatment to Boehringer in $870 Million Deal

publication date: Jul 1, 2019

Yuhan Corporation of South Korea out-licensed rights for its dual agonist NASH treatment to Boehringer Ingelheim in an agreement worth up to $870 million. BI will pay $40 million upfront and as much as $830 million in milestone payments, plus tiered royalties. The pre-clinical treatment is a first-in-class molecule that combines GLP-1 and FGF21 antagonists in a single molecule to reduce liver cell injury and hepatic inflammation by treating steatohepatitis while having direct anti-fibrotic effects. More details.....

Stock Symbol: (KRX: 000100)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.